A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts

Oncotarget

Volumn 7, Issue 11, 2016, Pages 12344-12358

  Azad, Babak Behnam ^a   Chatterjee, Samit ^a   Lesniak, Wojciech G ^a   Lisok, Ala ^a   Pullambhatla, Mrudula ^a   Bhujwalla, Zaver M ^a   Pomper, Martin G ^a   Nimmagadda, Sridhar ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cancer therapy; Chemokine receptor; Molecular imaging; Precision medicine; Zirconium 89

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CXCR4; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CXCR4; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ZIRCONIUM CXC CHEMOKINE RECEPTOR 4 MONOCLONAL ANTIBODY ZR 89; CXCR4 PROTEIN, HUMAN; RADIOISOTOPE; ZIRCONIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LYMPH NODE METASTASIS; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; A-549 CELL LINE; ANIMAL; CHEMISTRY; CHO CELL LINE; CRICETULUS; IMMUNOLOGY; LUNG TUMOR; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROCEDURES; RANDOMIZATION; SCID MOUSE; TUMOR CELL LINE; XENOGRAFT;

A549 CELLS; ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CHO CELLS; CRICETULUS; FEMALE; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED NOD; MICE, SCID; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RADIOPHARMACEUTICALS; RANDOM ALLOCATION; RECEPTORS, CXCR4; ZIRCONIUM;

EID: 84962910420     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7111     Document Type: Article

References (49)

1. Chatterjee S, Behnam Azad B, Nimmagadda S. The intricate role of CXCR4 in cancer. Advances in cancer research. 2014; 124:31-82.
2. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010; 16:2927-2931.
3. Wald O, Shapira OM, Izhar U. CXCR4/CXCL12 Axis in Non Small Cell Lung Cancer (NSCLC) Pathologic Roles and Therapeutic Potential. Theranostics. 2013; 3:26-33.
4. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, Luker GD. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 2004; 64:8604-8612.
5. Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, Horton LW, et al. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res. 2011; 71:603-613.
6. Cabioglu N, Sahin AA, Morandi P, Meric-Bernstam F, Islam R, Lin HY, Bucana CD, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M. Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol. 2009; 20:1013-1019.
7. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001; 410:50-56.
8. Zhang Z, Ni C, Chen W, Wu P, Wang Z, Yin J, Huang J, Qiu F. Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis. Bmc Cancer. 2014; 14:1-8.
9. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008; 83:584-594.
10. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non-small-cell lung cancer: recent developments. Lancet. 2013; 382:709-719.
11. Zhou X-m, He L, Hou G, Jiang B, Wang Y-h, Zhao L. Clinicopathological significance of CXCR4 in non-small cell lung cancer. Drug Design Development and Therapy. 2015; 9:1349-1358.
12. Spano JP, Andre F, Morat L, Sabatier L, Besse B, Combadiere C, Deterre P, Martin A, Azorin J, Valeyre D, Khayat D, Le Chevalier T, Soria JC. Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Annals of oncology/ESMO. 2004; 15:613-617.
13. Wagner PL, Hyjek E, Vazquez MF, Meherally D, Liu YF, Chadwick PA, Rengifo T, Sica GL, Port JL, Lee PC, Paul S, Altorki NK, Saqi A. CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. J Thorac Cardiovasc Surg. 2009; 137:615-621.
14. Su L, Zhang J, Xu H, Wang Y, Chu Y, Liu R, Xiong S. Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells. Clinical cancer research. 2005; 11:8273-8280.
15. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. The Stromal Derived Factor-1/CXCL12-CXC Chemokine Receptor 4 Biological Axis in Non-Small Cell Lung Cancer Metastases. Am J Respir Crit Care Med 2003; 167:1676-1686.
16. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1):4429-4434.
17. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008; 14:8010-8018.
18. Bosch A, Eroles P, Zaragoza R, Vina JR, Lluch A. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev. 2010; 36:206-215.
19. Chu QD, Panu L, Holm NT, Li BD, Johnson LW, Zhang S. High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome. J Surg Res. 2010; 159:689-695.
20. Zhao S, Chang SL, Linderman JJ, Feng FY, Luker GD. A Comprehensive Analysis of CXCL12 Isoforms in Breast Cancer. Transl Oncol. 2014; 7:429-438.
21. Huang EH, Singh B, Cristofanilli M, Gelovani J, Wei C, Vincent L, Cook KR, Lucci A. A CXCR4 Antagonist CTCE-9908 Inhibits Primary Tumor Growth and Metastasis of Breast Cancer (vol 155, pg 231, 2009). Journal of Surgical Research. 2010; 162:169-169.
22. Liang Z, Wu T, Lou H, Yu X, Taichman RS, Lau SK, Nie S, Umbreit J, Shim H. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Research. 2004; 64:4302-4308.
23. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EG, Walenkamp AM. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer. 2013; 49:219-230.
24. Kuil J, Buckle T, van Leeuwen FW. Imaging agents for the chemokine receptor 4 (CXCR4). Chem Soc Rev. 2012; 41:5239-5261.
25. Jacobson O, Weiss ID. CXCR4 chemokine receptor overview: biology, pathology and applications in imaging and therapy. Theranostics. 2013; 3:1-2.
26. Wester HJ, Keller U, Schottelius M, Beer A, Philipp-Abbrederis K, Hoffmann F, Simecek J, Gerngross C, Lassmann M, Herrmann K, Pellegata N, Rudelius M, Kessler H, Schwaiger M. Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging. Theranostics. 2015; 5:618-630.
27. Herrmann K, Lapa C, Wester HJ, Schottelius M, Schiepers C, Eberlein U, Bluemel C, Keller U, Knop S, Kropf S, Schirbel A, Buck AK, Lassmann M. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor. J Nucl Med. 2015; 56:410-416.
28. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012; 12:278-287.
29. Kuhne MR, Mulvey T, Belanger B, Chen S, Pan C, Chong C, Cao F, Niekro W, Kempe T, Henning KA, Cohen LJ, Korman AJ, Cardarelli PM. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clinical cancer research. 2013; 19:357-366.
30. Konishi S, Hamacher K, Vallabhajosula S, Kothari P, Bastidas D, Bander N, Goldsmith S. Determination of immunoreactive fraction of radiolabeled monoclonal antibodies: What is an appropriate method? Cancer Biotherapy and Radiopharmaceuticals. 2004; 19:706-715.
31. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. Journal of Immunological Methods. 1984; 72:77-89.
32. Salvucci O, Bouchard A, Baccarelli A, Deschenes J, Sauter G, Simon R, Bianchi R, Basik M. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat. 2006; 97:275-283.
33. Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O'Doherty M, et al. Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin's Lymphoma. New England Journal of Medicine. 2015; 372:1598-1607.
34. Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko S, CHeal SM, Beylergil V, Lefkowitz RA, Carrasquillo JA, Martinez DF, Fung AM, Solomon SB, Gonen M, Heller G, Loda M, Nanus D, Tagawa S, et al. A Phase I/II study for analytic validation of 89Zr-J591 immunoPET as a molecular imaging agent for metastatic prostate cancer. Clinical Cancer Research. 2015; 21:5277-5285.
35. Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK. CXCL12 (SDF1\(alpha\))-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies? Clin Cancer Res. 2011; 17:2074-2080.
36. Nimmagadda S, Pullambhatla M, Pomper MG. Immunoimaging of CXCR4 Expression in Brain Tumor Xenografts Using SPECT/CT. Journal of Nuclear Medicine. 2009; 50:1124-1130.
37. Jones PL, Brown BA, Sands H. Uptake and metabolism of 111In-labeled monoclonal antibody B6.2 by the rat liver. Cancer Res. 1990; 50(3 Suppl):852s-856s.
38. Abou DS, Ku T, Smith-Jones PM. In vivo biodistribution and accumulation of Zr-89 in mice. Nuclear Medicine and Biology. 2011; 38:675-681.
39. Munnink THO, Henstra MJ, Segerink LI, KMovig KLL, Brummelhuis-Visser P. Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: translating TNF-alpha experience to oncology. Clinical Pharamcology and Therapeutics. 2015:doi:10.1002/cpt.1211.
40. Rakha EA, El-Sayed ME, Green AR, Lee AHS, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007; 109:25-32.
41. Kato M, Kitayama J, Kazama S, Nagawa H. Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res. 2003; 5:R144-150.
42. Kang H, Watkins G, Douglas-Jones A, Mansel RE, Jiang WG. The elevated level of CXCR4 is correlated with nodal metastasis of human breast cancer. Breast. 2005; 14:360-367.
43. Yu S, Wang X, Liu G, Zhu X, Chen Y. High Level of CXCR4 in Triple-Negative Breast Cancer Specimens Associated with a Poor Clinical Outcome. Acta Medica Okayama. 2013; 67:369-375.
44. Holm NT, Byrnes K, Li BD, Turnage RH, Abreo F, Mathis JM, Chu QD. Elevated Levels of Chemokine Receptor CXCR4 in HER-2 Negative Breast Cancer Specimens Predict Recurrence. J Surg Res. 2007; 141:53-59.
45. Dehdashti F, Mortimer JE, Trinkaus K, Naughton MJ, Ellis M, Katzenellenbogen JA, Welch MJ, Siegel BA. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast cancer research and treatment. 2009; 113:509-517.
46. van Kruchten M, de Vries EGE, Brown M, de Vries EFJ, Glaudemans AWJM, Dierckx RAJO, Schroder CP, Hospers GAP. PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncology. 2013; 14:E465-E475.
47. Sorensen J, Sandberg D, Sandstrom M, Wennborg A, Feldwisch J, Tolmachev V, Astrom G, Lubberink M, Garske-Roman U, Carlsson J, Lindman H. First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the In-111-ABY-025 Affibody Molecule. Journal of Nuclear Medicine. 2014; 55:730-735.
48. Woodard LE, De Silva RA, Behnam Azad B, Lisok A, Pullambhatla M, W GL, Mease RC, Pomper MG, Nimmagadda S. Bridged cyclams as imaging agents for chemokine receptor 4 (CXCR4). Nucl Med Biol. 2014; 41:552-561.
49. Mordant P, Loriot Y, Lahon B, Castier Y, Leseche G, Soria J-C, Vozenin M-C, Decraene C, Deutsch E. Bioluminescent Orthotopic Mouse Models of Human Localized Non-Small Cell Lung Cancer: Feasibility and Identification of Circulating Tumour Cells. Plos One. 2011; 6(10).